Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders

Swati Pathak, Michael Roth, Amit K. Verma, Ulrich G. Steidl

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Eltrombopag (EP) is an orally bioavailable, non-peptide, thrombopoietin receptor (TPO-R) agonist developed to stimulate platelet production. EP is a small hydrazone molecule which interacts with the transmembrane domain of TPO-R and promotes megakaryopoiesis, and a subsequent increase in platelet number. To date, multiple large clinical trials have demonstrated the ability of EP to reduce the burden of thrombocytopenia and its associated side effects in patients with chronic immune thrombocytopenia purpura and patients with hepatitis-C related thrombocytopenia. Given these promising results and the morbidity associated with thrombocytopenia in cancer patients, there is significant interest in investigating the role of EP for thrombocytopenia secondary to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Areas covered: In this review, the authors address the potential utility of EP for patients with AML and MDS with thrombocytopenia. The review provides an overview of the rationale for the development of EP in AML and MDS, and the mechanism(s) of action of EP. The authors focus on preclinical data describing the effectiveness of EP as both a platelet-stimulating, and an anti-leukemia agent and describe the use of EP in clinical trials. Expert opinion: EP has the potential to be an effective supportive care agent, improving platelet counts and decreasing thrombocytopenia-related morbidity, in patients with AML and MDS. Large, randomized clinical trials are needed to assess the efficacy of EP in reducing the duration and severity of thrombocytopenia, as well assess the clinical utility of EP as an anti-leukemia agent.

Original languageEnglish (US)
Pages (from-to)1667-1675
Number of pages9
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume9
Issue number12
DOIs
StatePublished - Nov 2013

Fingerprint

Thrombocytopenia
Myelodysplastic Syndromes
Platelets
Acute Myeloid Leukemia
Therapeutics
Thrombopoietin Receptors
Platelet Count
eltrombopag
Leukemia
Blood Platelets
Clinical Trials
Morbidity
Hydrazones
Purpura
Idiopathic Thrombocytopenic Purpura
Expert Testimony
Hepatitis C
Randomized Controlled Trials
Molecules

Keywords

  • Eltrombopag
  • Non-peptide
  • Thrombocytopenia
  • Thrombopoietic factor

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

@article{86a09bde5092407ab7e04723c0bdc152,
title = "Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders",
abstract = "Introduction: Eltrombopag (EP) is an orally bioavailable, non-peptide, thrombopoietin receptor (TPO-R) agonist developed to stimulate platelet production. EP is a small hydrazone molecule which interacts with the transmembrane domain of TPO-R and promotes megakaryopoiesis, and a subsequent increase in platelet number. To date, multiple large clinical trials have demonstrated the ability of EP to reduce the burden of thrombocytopenia and its associated side effects in patients with chronic immune thrombocytopenia purpura and patients with hepatitis-C related thrombocytopenia. Given these promising results and the morbidity associated with thrombocytopenia in cancer patients, there is significant interest in investigating the role of EP for thrombocytopenia secondary to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Areas covered: In this review, the authors address the potential utility of EP for patients with AML and MDS with thrombocytopenia. The review provides an overview of the rationale for the development of EP in AML and MDS, and the mechanism(s) of action of EP. The authors focus on preclinical data describing the effectiveness of EP as both a platelet-stimulating, and an anti-leukemia agent and describe the use of EP in clinical trials. Expert opinion: EP has the potential to be an effective supportive care agent, improving platelet counts and decreasing thrombocytopenia-related morbidity, in patients with AML and MDS. Large, randomized clinical trials are needed to assess the efficacy of EP in reducing the duration and severity of thrombocytopenia, as well assess the clinical utility of EP as an anti-leukemia agent.",
keywords = "Eltrombopag, Non-peptide, Thrombocytopenia, Thrombopoietic factor",
author = "Swati Pathak and Michael Roth and Verma, {Amit K.} and Steidl, {Ulrich G.}",
year = "2013",
month = "11",
doi = "10.1517/17425255.2013.858119",
language = "English (US)",
volume = "9",
pages = "1667--1675",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders

AU - Pathak, Swati

AU - Roth, Michael

AU - Verma, Amit K.

AU - Steidl, Ulrich G.

PY - 2013/11

Y1 - 2013/11

N2 - Introduction: Eltrombopag (EP) is an orally bioavailable, non-peptide, thrombopoietin receptor (TPO-R) agonist developed to stimulate platelet production. EP is a small hydrazone molecule which interacts with the transmembrane domain of TPO-R and promotes megakaryopoiesis, and a subsequent increase in platelet number. To date, multiple large clinical trials have demonstrated the ability of EP to reduce the burden of thrombocytopenia and its associated side effects in patients with chronic immune thrombocytopenia purpura and patients with hepatitis-C related thrombocytopenia. Given these promising results and the morbidity associated with thrombocytopenia in cancer patients, there is significant interest in investigating the role of EP for thrombocytopenia secondary to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Areas covered: In this review, the authors address the potential utility of EP for patients with AML and MDS with thrombocytopenia. The review provides an overview of the rationale for the development of EP in AML and MDS, and the mechanism(s) of action of EP. The authors focus on preclinical data describing the effectiveness of EP as both a platelet-stimulating, and an anti-leukemia agent and describe the use of EP in clinical trials. Expert opinion: EP has the potential to be an effective supportive care agent, improving platelet counts and decreasing thrombocytopenia-related morbidity, in patients with AML and MDS. Large, randomized clinical trials are needed to assess the efficacy of EP in reducing the duration and severity of thrombocytopenia, as well assess the clinical utility of EP as an anti-leukemia agent.

AB - Introduction: Eltrombopag (EP) is an orally bioavailable, non-peptide, thrombopoietin receptor (TPO-R) agonist developed to stimulate platelet production. EP is a small hydrazone molecule which interacts with the transmembrane domain of TPO-R and promotes megakaryopoiesis, and a subsequent increase in platelet number. To date, multiple large clinical trials have demonstrated the ability of EP to reduce the burden of thrombocytopenia and its associated side effects in patients with chronic immune thrombocytopenia purpura and patients with hepatitis-C related thrombocytopenia. Given these promising results and the morbidity associated with thrombocytopenia in cancer patients, there is significant interest in investigating the role of EP for thrombocytopenia secondary to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Areas covered: In this review, the authors address the potential utility of EP for patients with AML and MDS with thrombocytopenia. The review provides an overview of the rationale for the development of EP in AML and MDS, and the mechanism(s) of action of EP. The authors focus on preclinical data describing the effectiveness of EP as both a platelet-stimulating, and an anti-leukemia agent and describe the use of EP in clinical trials. Expert opinion: EP has the potential to be an effective supportive care agent, improving platelet counts and decreasing thrombocytopenia-related morbidity, in patients with AML and MDS. Large, randomized clinical trials are needed to assess the efficacy of EP in reducing the duration and severity of thrombocytopenia, as well assess the clinical utility of EP as an anti-leukemia agent.

KW - Eltrombopag

KW - Non-peptide

KW - Thrombocytopenia

KW - Thrombopoietic factor

UR - http://www.scopus.com/inward/record.url?scp=84888123800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888123800&partnerID=8YFLogxK

U2 - 10.1517/17425255.2013.858119

DO - 10.1517/17425255.2013.858119

M3 - Article

VL - 9

SP - 1667

EP - 1675

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 12

ER -